Skip to Content

Feiba NF (anti-inhibitor coagulant complex) Disease Interactions

There is 1 disease interaction with Feiba NF (anti-inhibitor coagulant complex):

Major

Anti- inhibitor coagulation (Includes Feiba NF) ↔ thrombo/hemorrhage

Severe Potential Hazard, High plausibility. Applies to: History - Thrombotic/Thromboembolic Disorder, Thrombotic/Thromboembolic Disorder, Disseminated Intravascular Coagulation, Myocardial Infarction, Pulmonary Embolism

The use of anti- inhibitor coagulant complex is contraindicated in patients with significant signs of fibrinolysis, disseminated intravascular coagulation (DIC), and acute thrombosis or embolism including myocardial infarction. Anti- inhibitor coagulant complex contains Factor VIII inhibitor bypassing activity and prothrombin complex factors and may cause or exacerbate fibrinolysis or coagulation. If DIC or fibrinolysis occurs during treatment, the infusion should be stopped promptly and appropriate therapeutic measures initiated. Thromboembolic events may also occur during treatment, particularly following the administration of large doses and/or in patients with thrombotic risk factors. Caution is advised when administering anti- inhibitor coagulant complex to patients with an active or past history of thromboembolic disorders.

References

  1. "Product Information. Autoplex T (anti-inhibitor coagulant complex)." Nabi, Boca Raton, FL.

Feiba NF (anti-inhibitor coagulant complex) drug interactions

There are 5 drug interactions with Feiba NF (anti-inhibitor coagulant complex)

More about Feiba NF (anti-inhibitor coagulant complex)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide